---
schema_version: "secwatch.filing_event.v1"
accession: "0001185185-22-000608"
form_type: "8-K"
ticker: "IGC"
cik: "0001326205"
company_name: "IGC Pharma, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T17:50:21.543586+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# IGC subsidiary licenses NMI compounds from JNCASR for Alzheimer's treatment

## Summary
- Hamsa Biopharma (IGC subsidiary) obtains exclusive worldwide license for NMI Compounds from JNCASR.
- NMI Compounds are small molecule inhibitors that may reduce amyloid neurotoxicity, targeting Alzheimer's and other CNS disorders.
- License fee of INR [***] with milestone payment upon FDA Phase II approval; royalties of [***]% of Net Revenue.
- IGC gains rights to prosecute patents, use all licensor technology, and first refusal on future CNS inventions.
- Agreement includes sublicensing rights and term until last patent expiration.

## SEC filing metadata
- accession: 0001185185-22-000608
- form_type: 8-K
- ticker: IGC
- cik: 0001326205
- company_name: IGC Pharma, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326205/000118518522000608/0001185185-22-000608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326205/000118518522000608/indiaglob20220512_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001185185-22-000608
- JSON: https://secwatch.observer/filing/0001185185-22-000608.json
- Plain text: https://secwatch.observer/filing/0001185185-22-000608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.